Testagen vs Semaglutide
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
TestagenGLP-1 / Weight Loss Agonists
Semaglutide- Summary
- Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
- Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~7 days
- Admin Route
- SubQ, Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
- Frequency
- Daily for 10–30 days
- Once weekly, subcutaneous
- Key Benefits
- Supports endogenous testosterone synthesis via Leydig cell normalization
- Promotes spermatogenesis and sperm quality
- Anti-aging effects on testicular tissue
- May attenuate age-related testosterone decline
- Mechanistically distinct from TRT — does not suppress HPG axis
- Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
- Supports male fertility without exogenous hormone replacement
- Average 15–20% body weight reduction in clinical trials (STEP trials)
- Significant reduction in appetite and food cravings
- Improvement in blood sugar control and insulin sensitivity
- Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
- May reduce risk of kidney disease
- Improves metabolic markers (cholesterol, blood pressure)
- FDA-approved — extensively studied with robust safety data
- Weekly dosing convenience
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant endocrine disruption reported at standard doses
- Nausea (most common, especially during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort
- +4 more
- Stacks With
- —
- —